Photo by mertguller from unsplash
The authors of this article [1] report an error in the description of the methods for the antiretroviral (ARV) drugs used in the pharmacokinetic (PK) study in mice. The mice… Click to show full abstract
The authors of this article [1] report an error in the description of the methods for the antiretroviral (ARV) drugs used in the pharmacokinetic (PK) study in mice. The mice in the PK study of ARVs in solution received emtricitabine (FTC) in addition to tenofovir alafenamide (TAF) and elvitegravir (EVG) and this was not reported in the article. The mice in the PK study of ARVs in nanoformulation received only TAFþEVG. Finally, administration of ARVs in solution was not part of the approved IACUC approval (IACUC #0989). IACUC approval was for PK of ARV in the nanoformulation. The omission that the mice received these 3 drugs in solution, means that the legend for Fig. 2 is modified to include ‘‘with emtricitabine’’ in the description for Fig. 2b. and should be as follows:
Journal Title: AIDS
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!